Your browser is no longer supported. Please, upgrade your browser.
ONCE Spark Therapeutics, Inc. daily Stock Chart
Spark Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.18 Insider Own6.70% Shs Outstand37.99M Perf Week-0.16%
Market Cap4.32B Forward P/E- EPS next Y-4.17 Insider Trans-44.00% Shs Float35.33M Perf Month115.41%
Income-78.80M PEG- EPS next Q-1.18 Inst Own99.68% Short Float7.04% Perf Quarter183.54%
Sales64.70M P/S66.74 EPS this Y72.30% Inst Trans-1.43% Short Ratio1.48 Perf Half Y92.82%
Book/sh13.18 P/B8.62 EPS next Y15.40% ROA-10.20% Target Price98.44 Perf Year68.38%
Cash/sh11.94 P/C9.52 EPS next 5Y17.00% ROE-14.90% 52W Range34.53 - 114.20 Perf YTD190.42%
Dividend- P/FCF- EPS past 5Y2.90% ROI-35.40% 52W High-0.46% Beta2.57
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin87.80% 52W Low229.19% ATR2.47
Employees368 Current Ratio9.10 Sales Q/Q78.40% Oper. Margin- RSI (14)90.00 Volatility0.27% 1.26%
OptionableYes Debt/Eq0.10 EPS Q/Q0.70% Profit Margin- Rel Volume0.85 Prev Close113.96
ShortableYes LT Debt/Eq0.09 EarningsFeb 19 BMO Payout- Avg Volume1.68M Price113.67
Recom2.80 SMA2012.42% SMA5067.92% SMA20084.94% Volume1,432,952 Change-0.25%
Feb-25-19Downgrade Cantor Fitzgerald Overweight → Neutral $80 → $114.50
Jan-10-19Reiterated Cantor Fitzgerald Overweight $103 → $80
Nov-16-18Upgrade Credit Suisse Underperform → Neutral
Nov-07-18Upgrade Wedbush Underperform → Neutral $40
Nov-07-18Upgrade Raymond James Outperform → Strong Buy
Nov-07-18Upgrade B. Riley FBR Neutral → Buy $68 → $71
Oct-10-18Initiated Guggenheim Buy
Aug-08-18Reiterated Stifel Buy $76 → $68
Aug-08-18Reiterated Chardan Capital Markets Neutral $60 → $85
Aug-07-18Upgrade Citigroup Neutral → Buy
Aug-07-18Downgrade Credit Suisse Outperform → Underperform
Jul-19-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Jun-28-18Initiated B. Riley FBR, Inc. Neutral $74
May-09-18Reiterated Barclays Overweight $64 → $85
May-01-18Initiated Citigroup Neutral $85
Apr-23-18Downgrade Chardan Capital Markets Buy → Neutral $80 → $85
Feb-21-18Reiterated Stifel Buy $73 → $64
Feb-14-18Downgrade JP Morgan Overweight → Neutral
Feb-13-18Initiated Mizuho Buy $79
Feb-08-18Resumed RBC Capital Mkts Outperform $65
Mar-18-19 04:20PM  Spark Unlikely To Get A Better Bid But These Stocks Could Be In Play Investor's Business Daily
Mar-14-19 11:21AM  Life Sciences Pa. reveals awards for its top CEO, top products and deal of the year American City Business Journals
Mar-12-19 11:54AM  SPARK THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout GlobeNewswire
Mar-11-19 10:24PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Spark Therapeutics, Inc. - ONCE PR Newswire
Mar-10-19 10:36AM  10 Stocks For The Gene Therapy Revolution Investopedia
Mar-08-19 10:40AM  Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next? Motley Fool
09:35AM  Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC Zacks
08:00AM  Rare Disease Therapies Draw Big Biopharma's Interest ACCESSWIRE
Mar-07-19 11:36AM  Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash GlobeNewswire
Mar-06-19 01:19PM  The Roche Merger Will Do Wonders for Spark Stock InvestorPlace
Mar-05-19 04:53PM  Biogen to Acquire Gene-Therapy Company Nightstar for $800M Zacks
01:09PM  Why Spark Therapeutics Stock Soared 137% in February Motley Fool
Mar-04-19 02:50PM  Biotech stocks are tracking for their best quarter ever here's how to play it CNBC
12:27PM  MERGER ALERT LABL and ONCE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies GlobeNewswire
Mar-01-19 08:38PM  [$$] The Side Effects of Million-Dollar Drugs The Wall Street Journal
09:29AM  Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices Zacks
08:30AM  [$$] The Side Effects of Million-Dollar Drugs The Wall Street Journal
Feb-27-19 04:25PM  Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates Zacks
09:53AM  The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure Zacks
Feb-26-19 05:51PM  MERGER ALERT LABL, CMTA and ONCE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies GlobeNewswire
02:00PM  Whose wallets will be fattened by the sale of Spark Therapeutics? American City Business Journals
12:54PM  SPARK THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout Business Wire
11:15AM  Biotech ETFs Jump on Roche-Spark Deal Zacks
09:30AM  Company News For Feb 26, 2019 Zacks
08:54AM  5 Gene Therapy Stocks to Enrich Your Portfolio Zacks
07:19AM  2 More Gene Therapy Stocks on Big Pharma's Buyout Radar Motley Fool
Feb-25-19 07:51PM  [$$] Why There Is No Sticker Shock in Biotech The Wall Street Journal +120.09%
06:07PM  Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Spark Therapeutics, Inc. (ONCE) on Behalf of Stockholders and Encourages ONCE Investors to Contact the Firm GlobeNewswire
05:48PM  Mario Gabelli's take on today's flurry of M&A activity CNBC Videos
05:08PM  Children's Hospitals $50 Million Bet Turns Into a $456 Million Payday Bloomberg
05:04PM  Stock Market Today: Roche Buys Spark Therapeutics and Investors Digest Berkshire's Annual Letter Motley Fool
04:36PM  Spark and GE rise while Barrick Gold slides Associated Press
04:19PM  3 Things to Know at Market Close: ETF Inflows, Spark Therapeutics, Palo Alto
04:09PM  Roche Is Buying Spark Now These Other Gene Therapy Stocks Are In Play Investor's Business Daily
04:06PM  Dow Closes Modestly Higher After Trump Extends China Tariff Deadline
03:12PM  Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal Benzinga
02:21PM  Here's Why Gene Therapy Stocks Are Soaring Today Motley Fool
01:17PM  Roche 'steps up' for gene therapy with $4.3 bln Spark bet Reuters
12:53PM  Why Investors Should Cash Out Of This Soaring Biotech Stock
12:03PM  Why Spark Therapeutics Is Skyrocketing 120% Today Motley Fool
11:37AM  Spark Therapeutics Rockets as Roche Pays $4.3 Billion for Gene Therapy Experts
11:29AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Spark Therapeutics, Inc. to Roche is Fair to Shareholders GlobeNewswire
11:17AM  Gene-therapy stocks surge on Roche-Spark deal MarketWatch
11:02AM  Roche Bids $4.8 Billion for Spark and Its Gene Therapy Bloomberg
09:12AM  Spark Therapeutics Stock Doubles, Netflix Gains and More Monday Morning Movers
08:56AM  Pharma M&A Wave: Spark Therapeutics, Clementia Pharma Among The Rare Disease Biotechs Acquired Benzinga
08:33AM  [$$] Why There Is No Sticker Shock in Biotech The Wall Street Journal
08:33AM  Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died
08:31AM  Roche (RHHBY) to Acquire Spark Therapeutics for $4.8 Billion Zacks
08:06AM  Roche bets $4.3 bln on Spark in gene therapy move Reuters Videos
08:05AM  Trade Talks, Spark, Buffett, Kraft Heinz, 'Green Book' - 5 Things You Must Know
07:19AM  Roche 'steps up' for gene therapy with $4.3 bln Spark bet Reuters
06:46AM  Roche to purchase gene therapy firm Spark in $4.3 billion deal CNBC Videos
06:29AM  Stocks Gain, China Surges, as Trump Delays Tariffs Amid Trade Talk Progress
04:02AM  Roche bets $4.3 billion on Spark in gene therapy move Reuters
03:28AM  Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3 billion Reuters
03:03AM  [$$] Roche to buy US biotech Spark Therapeutics in $4.8bn deal Financial Times
01:38AM  Roche Has a $5 Billion Chance to Lead on Drug Prices Bloomberg
01:28AM  Roche to Buy Spark for $4.8 Billion
01:15AM  Roche to buy gene therapy specialist Spark in $4.3 bln deal Reuters
01:01AM  Roche enters into definitive merger agreement to acquire Spark Therapeutics GlobeNewswire
01:00AM  Spark Therapeutics Enters into Definitive Merger Agreement with Roche GlobeNewswire
Feb-24-19 08:38PM  [$$] Roche Agrees to Buy Biotech Firm Spark Therapeutics The Wall Street Journal
12:45PM  Roche Aims to Buy Spark for $5 Billion: Wall Street Journal
Feb-23-19 06:36PM  Roche nearing $5 billion deal to acquire Spark Therapeutics - WSJ Reuters
02:10PM  Report: Pharmaceutical giant close to deal for Philadelphia's Spark Therapeutics American City Business Journals
01:25PM  [$$] Roche Nears Deal to Buy Spark Therapeutics for Close to $5 Billion The Wall Street Journal
Feb-22-19 08:11AM  Inside Spark's quest to set the standards for gene therapy payments American City Business Journals
Feb-21-19 09:44AM  Edited Transcript of ONCE earnings conference call or presentation 19-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
08:25AM  New Research Coverage Highlights General Electric, Redfin, Splunk, Spark Therapeutics, Innospec, and Hemispherx BioPharma Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Feb-19-19 05:17PM  Spark Therapeutics (ONCE) Q4 2018 Earnings Conference Call Transcript Motley Fool
10:07AM  Sales of Philadelphia-born gene therapy product hit $27M during first year American City Business Journals
07:30AM  Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress GlobeNewswire
06:30AM  Spark Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-12-19 10:30AM  Spark Therapeutics (ONCE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks
07:30AM  Spark Therapeutics to Host Conference Call on Tuesday, Feb. 19 at 8:30 a.m. ET to Discuss 2018 Results and Recent Business Highlights GlobeNewswire
Feb-08-19 04:14PM  This Gene Therapy Stock Could Soon Hit The Auction Block Here's Why Investor's Business Daily
Feb-01-19 01:30PM  Gene Therapy: Novartis Under The Microscope With Novel Treatment Investor's Business Daily
Jan-31-19 12:48PM  Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y Zacks
07:30AM  Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium GlobeNewswire
Jan-23-19 12:05PM  Calculating The Intrinsic Value Of Spark Therapeutics, Inc. (NASDAQ:ONCE) Simply Wall St.
Jan-12-19 09:41AM  Here's What Pushed bluebird bio Stock Down 44.3% in 2018 Motley Fool
Jan-11-19 02:00PM  Edited Transcript of ONCE earnings conference call or presentation 9-May-17 12:30pm GMT Thomson Reuters StreetEvents
02:00PM  Edited Transcript of ONCE earnings conference call or presentation 6-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Jan-02-19 07:30AM  Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference GlobeNewswire
Dec-31-18 08:31AM  Novartis (NVS) Benefits From New Drugs & Key Acquisitions Zacks
Dec-21-18 08:51AM  Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer Zacks -7.50%
Dec-11-18 03:17PM  Top 6 Performing IPOs of 2015 (ONCE, GBT) Investopedia
Dec-03-18 06:33AM  Spark Therapeutics CEO on breakthroughs in gene therapy CNBC Videos
Dec-02-18 07:30PM  Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition GlobeNewswire
Nov-29-18 01:39PM  Bayer To Cut 12,000 Jobs Amid Strategic Overhaul To Focus On Pharma Investor's Business Daily
Nov-28-18 08:22AM  Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News Zacks
07:40AM  Analysis: Positioning to Benefit within Real Goods Solar, Natural Resource Partners LP, Spark Therapeutics, Social Reality, Rapid7, and BiondVax Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-26-18 03:16PM  Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss Zacks
07:25AM  European approval of Spark Therapeutics' gene therapy triggers $25M payment American City Business Journals
Nov-23-18 01:07PM  Is Spark Therapeutics Incs (NASDAQ:ONCE) CEO Being Overpaid? Simply Wall St.
01:15AM  European Commission Approves Spark Therapeutics LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations GlobeNewswire
Nov-14-18 08:19AM  Sangamo stock drops after J.P. Morgan downgrade MarketWatch
Nov-12-18 04:21PM  These Biopharmas Could Cure Genetic Diseases At $5 Million Apiece Investor's Business Daily
Nov-06-18 09:30AM  Spark Therapeutics (ONCE) Reports Q3 Loss, Misses Revenue Estimates Zacks -5.32%
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells. The company's gene therapy product candidates comprise SPK-8011 and SPK-8016 for hemophilia; SPK-7001 for choroideremia; and SPK-9001 for hemophilia B. It is also developing other liver-directed gene therapies, including SPK-3006 for Pompe disease; and neurodegenerative disease product candidates to address Huntington's disease and others, as well as TPP1 deficiency, which is a form of Batten disease. The company's preclinical programs targets inherited retinal diseases, including Stargardt's disease. The company has collaboration agreement with Pfizer, Inc. for the development and commercialization of SPK-FIX product candidates in its gene therapy program for the treatment of hemophilia B. It also has licensing and commercialization agreement with Novartis to develop and commercialize voretigene neparvovec outside the United States. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Marrazzo Jeffrey DChief Executive OfficerMar 15Option Exercise3.4549,940172,293355,215Mar 19 05:26 PM
Children's Hospital of Philade10% OwnerFeb 27Sale113.002,000,000226,000,0001,954,957Mar 01 04:18 PM
Mehra AnandDirectorJan 04Option Exercise3.4537,203128,35038,703Jan 08 04:30 PM
Marrazzo Jeffrey DChief Executive OfficerDec 28Option Exercise3.456,00020,700299,354Jan 02 05:12 PM
Altschuler StevenDirectorMay 31Option Exercise0.001,500026,500May 31 09:29 PM
Furey JohnChief Operating OfficerApr 20Option Exercise49.746,723334,4026,723Apr 24 04:30 PM
Furey JohnChief Operating OfficerApr 20Sale82.506,723554,6480Apr 24 04:30 PM
Furey JohnChief Operating OfficerApr 18Option Exercise49.7411,000547,14011,000Apr 19 04:23 PM
Furey JohnChief Operating OfficerApr 18Sale82.5311,000907,8300Apr 19 04:23 PM
Furey JohnChief Operating OfficerApr 17Option Exercise49.742,277113,2582,277Apr 19 04:23 PM
Furey JohnChief Operating OfficerApr 17Sale82.502,277187,8530Apr 19 04:23 PM
Furey JohnChief Operating OfficerApr 12Option Exercise49.7420,000994,80020,000Apr 16 05:52 PM
Furey JohnChief Operating OfficerApr 12Sale77.5120,0001,550,2000Apr 16 05:52 PM